Article
4 Things To Know About SCOTUS Case That Could End Birthright Citizenship
4 Things To Know About SCOTUS Case That Could End Birthright Citizenship
Authored by Sam Dorman via The Epoch Times (emphasis ours),
The Supreme Court is set to consider a landmark case challenging President Donald Trump’s bid to limit birthright citizenship.
The Supreme Court in Washington on Feb. 21, 2026. Madalina Kilroy/The Epoch Times
The case, known as Trump v. Barbara, is set for oral argument on April 1.
Upon entering office, Trump signed an order barring the children of illegal immigrants born in the United States from securing citizenship. It also applies to...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Aug 3, 2026 / Tyler Durden
Futures Rise As Oil Plunge Helps Yields Ease From Nosebleed Highs; All Eyes On Yentervention
Futures Rise As Oil Plunge Helps Yields Ease From Nosebleed Highs; All Eyes On Yentervention
Futures are higher with both tech and small caps outperforming as Trump points to a deal/advanded discussions with Iran (which Iran is naturally denying), which is helping push energy prices and bond yields lower as the USD depreciates. As of 8:00am ET, S&P futures are up 0.5% while Nasdaq futures rise 0.4% led by Mag 7 stocks higher with Semis lagging. Energy is lower with the remaining sectors seeing a bid pre-mkt as the lower...
Read more
May 15, 2026 / Tyler Durden
AI Bots Placed In Virtual Town For 2 Weeks Go Apesh*t, Prompting Concerns
Apr 24, 2026 / Tyler Durden
FDA Approves First Gene Therapy To Treat Deafness
FDA Approves First Gene Therapy To Treat Deafness
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
Federal regulators on Thursday approved the first gene therapy to restore hearing, just two months after the therapy’s maker formally requested a license.
Dr. Marty Makary, the Food and Drug Administration's commissioner, in an undated file photograph. Madalina Vasiliu/The Epoch Times
The Food and Drug Administration approved the Regeneron therapy, Otarmeni, for children and adults with severe or profound hearing loss associated with OTOF gene variants.
The approval came 61 days after Regeneron filed for a...
Read more




